Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England
Open accessThe DOI matches its Crossref record; 3 of the 3 references it cites were found in a registry or an index.
Abstract
Adults receiving heterologous COVID-19 immunisation with mRNA (Comirnaty) or adenoviral-vector (Vaxzevria) vaccines had higher reactogenicity rates and sought medical attention more often after two doses than homologous schedules. Reactogenicity was higher among ≤ 50 than > 50 year-olds, women and those with prior symptomatic/confirmed COVID-19. Adults receiving heterologous schedules on clinical advice after severe first-dose reactions had lower reactogenicity after dose 2 following Vaxzevria/Comirnaty (93.4%; 95% confidence interval: 90.5–98.1 vs 48% (41.0–57.7) but not Comirnaty/Vaxzevria (91.7%; (77.5–98.2 vs 75.0% (57.8–87.9).
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine
Polack, F. P., Thomas, S. J., Kitchin, N., Absalon, J., Gurtman, A., Lockhart, S., Perez, J. L., Pérez Marc, G., Moreira, E. D., Zerbini, C., et al. (2020) · New England Journal of Medicine · doi:10.1056/nejmoa2034577 · Cited by 14,592
Folegatti, P. M., Ewer, K. J., Aley, P. K., Angus, B., Becker, S., Belij-Rammerstorfer, S., Bellamy, D., Bibi, S., Bittaye, M., Clutterbuck, E. A., et al. (2020) · The Lancet · doi:10.1016/s0140-6736(20)31604-4 · Cited by 2,419
Spencer, A. J., McKay, P. F., Belij-Rammerstorfer, S., Ulaszewska, M., Bissett, C. D., Hu, K., Samnuan, K., Blakney, A. K., Wright, D., Sharpe, H. R., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23173-1 · Cited by 125
Cited by
Duration of Protection against Mild and Severe Disease by Covid-19 Vaccines
Andrews, N., Tessier, E., Stowe, J., Gower, C., Kirsebom, F., Simmons, R., Gallagher, E., Thelwall, S., Groves, N., Dabrera, G., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2115481 · Cited by 807
Self-citationReal-world data: A brief review of the methods, applications, challenges and opportunities
Liu, F., & Panagiotakos, D. (2022) · BMC Medical Research Methodology · doi:10.1186/s12874-022-01768-6 · Cited by 496
“…the COVID-19 pandemic, RWD are used to generate or aid the generation of real-world evidence (RWE) on the effectiveness of COVID-19 vaccination [3–5], to model localized COVID-19 con-trol strategies [6], to characterize COVID-19 and flu using data from smartphones and wearables [7], to study…”
MethodAn exploratory analysis of the response to ChAdOx1 nCoV-19 (AZD1222) vaccine in males and females
Marchevsky, N. G., Li, G., Aley, P., Costa Clemens, S. A., Barrett, J. R., Belij-Rammerstorfer, S., Bibi, S., Clutterbuck, E., Dold, C., Felle, S., et al. (2022) · eBioMedicine · doi:10.1016/j.ebiom.2022.104128 · Cited by 17
Metadata
- Authors
- Powell, A. A., Power, L., Westrop, S., McOwat, K., Campbell, H., Simmons, R., Ramsay, M. E., Brown, K., Ladhani, S. N., & Amirthalingam, G.
- Venue
- Eurosurveillance
- Published
- 2021-07-15
- Volume
- 26
- Issue
- 28
- ISSN
- 1025-496X (ISSN-L)
- 1560-7917
- OpenAlex
- W3177694513
- Cited by
- 58
- References
- 3
- FWCI
- 4.07
- Type
- journal article
- Language
- en
- Open access
- diamond
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England. https://app.cochat.ai/papers/10.2807/1560-7917.es.2021.26.28.2100634
- The paper
- Powell, A. A., Power, L., Westrop, S., McOwat, K., Campbell, H., Simmons, R., Ramsay, M. E., Brown, K., Ladhani, S. N., & Amirthalingam, G. (2021). Real-world data shows increased reactogenicity in adults after heterologous compared to homologous prime-boost COVID-19 vaccination, March−June 2021, England. Eurosurveillance. https://doi.org/10.2807/1560-7917.es.2021.26.28.2100634
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.